mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC

NCT04895137 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Immunotherapy

Interventions

DRUG: mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University